Trial Profile
Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 22 Feb 2016 Primary endpoint has been met. (Reduction degree of UC-DAI), as per an article published in the Advances in Therapy.
- 22 Feb 2016 Results published in the Advances in Therapy
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.